UNSPSC 51361502: Cloretate or clorethate

This classification denotes a sedative and hypnotic with the molecular formula C5H4Cl6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9VY0HXB11T, chemically known as 2,2,2-trichloroethyl carbonate but generally known as cloretate, which bears US NIH Compound Identifier 21851. European Medicines Agency schedules Cloretate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06753MIG. The term CLORETATE is an International Non-Proprietary Name.

CLORETATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cloretate or clorethate bears US NLM identifiers UMLS ID C0636116 and NCI Concept Code C80671. SMILES: C(C(CL)(CL)CL)OC(=O)OCC(CL)(CL)CL.

UNSPSC 51361502 Cloretate or clorethate, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope; the recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals distribution through wholesale channels — none of which match the chemical or pharmaceutical intermediate product this code names. State and local governments buying under this code would typically source chemical compounds for pharmaceutical manufacturing, laboratory use, or industrial applications, but the three recent solicitations in the opportunity block address pharmaceutical products, health-system supply chains, and prescription benefit administration rather than chemical precursors or intermediates. The issuing bodies span a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance, administered by the Minnesota Department of Administration) — indicating that when activity does occur under this code, it crosses multiple jurisdiction types and geographic regions.

Geographic activity appears concentrated in the South and Upper Midwest, with recent solicitations from Florida, Texas, and Minnesota; however, the Minnesota MMCAP procurement extends eligibility to participating state and local governments including Oregon, broadening the practical geographic scope. Representative recent opportunities include Seminole County's IFB 60459723LAS for naloxone and drug deactivation systems (due July 26, 2023) and the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). The Texas HHS Commission's RFI HHS0017013 on direct-to-manufacturer prescriptions (due April 3, 2026) represents exploratory procurement activity. Given the mismatch between the code's stated scope and the actual products being solicited, this code warrants careful review during opportunity screening — vendors sourcing cloretate or clorethate for pharmaceutical or industrial use would find little relevant demand signal in recent state and local procurement under this taxonomy code.